Danicopan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Comment on "Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)".

Comment on "Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 21, 2026

Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria.

Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria.

Journal: Drug design, development and therapy

Published: May 15, 2026

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: March 26, 2026

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

Journal: HemaSphere

Published: March 02, 2026

Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria.

Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria.

Journal: EJHaem

Published: January 17, 2026

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 12, 2026

Systemic medications and their impact on age-related macular degeneration development and progression: a review of current evidence.

Systemic medications and their impact on age-related macular degeneration development and progression: a review of current evidence.

Journal: Current opinion in ophthalmology

Published: January 02, 2026

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Journal: Kidney & blood pressure research

Published: November 28, 2025

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab.

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 04, 2025

Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.

Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.

Journal: Expert opinion on biological therapy

Published: October 13, 2025

Complement factor D is a drug target for metabolic-associated fatty liver disease.

Complement factor D is a drug target for metabolic-associated fatty liver disease.

Journal: Molecular immunology

Published: October 09, 2025

Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026